Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Blog Article

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation.Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone.Direct and indirect costs were included in the model.

The effects were expressed in Quality-Adjusted Life Years adjusted for side effects.Results Compared to androgen deprivation therapy alone, Horse Weight Tapes the addition of chemotherapy and of abiraterone generated 0.492 and 0.

999, respectively, in Quality-Adjusted Life Years.Abiraterone led LIP SERUM to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel.

The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.

379,42 for abiraterone compared to docetaxel, respectively.Conclusion The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy.However, discounts on abiraterone cost might improve cost-effectiveness.